Results 61 to 68 of about 177 (68)

Advancements and challenges in antifungal therapeutic development. [PDF]

Clin Microbiol Rev
Puumala E, Fallah S, Robbins N, Cowen LE.   +3 more
europepmc   +1 more source

Errata. [PDF]

J Infect Dis, 2018
europepmc   +1 more source

Overcoming Global Antifungal Challenges: Medical and Agricultural Aspects. [PDF]

ACS Bio Med Chem Au
Galgóczy L.
europepmc   +1 more source

A novel pan-fungal screening platform for antifungal drug discovery: proof of principle study. [PDF]

Antimicrob Agents Chemother
Inman R, Warris A, Bignell E.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus

International Journal of Antimicrobial Agents, 2020
In recent decades, invasive infections caused by fungal pathogens have been reported with increasing frequency. Concurrently, the rates of detected resistance mechanisms against commonly used antifungal agents in fungi are increasing. The need for novel antifungal drugs is thus imminent.
Kirchhoff, Lisa, Dittmer, Silke, Buer, Jan, Rath, Peter-Michael, Steinmann, Jörg   +4 more
openaire   +2 more sources

Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical isolates, and review of azole resistance phenotype and genotype epidemiology in China.

2021
Triazole resistance in A. fumigatus is an increasing worldwide problem that causes major challenges in the management of aspergillosis. New antifungal drugs are needed with novel targets, that are effective in triazole-resistant infection. In this study, we retrospectively evaluated potency of the novel drug olorofim compared to contemporary antifungal
Su, Huilin, Zhu, Min, Tsui, Clement Kin-Ming, van der Lee, Henrich, Tehupeiory-Kooreman, Marlou, Zoll, Jan, Engel, Tobias, Li, Li, Zhu, Junhao, Lu, Zihan, Zhang, Qiangqiang, Verweij, Paul E, Deng, Shuwen   +12 more
openaire   +1 more source

In vitro activity of F901318 against filamentous fungi from cystic fibrosis patients

2018
Steinmann, Jörg, Dittmer, S., Heep, M., Rath, Peter-Michael   +3 more
openaire   +2 more sources

Activity of F901318 against azole-resistant and other difficult-to-treat Aspergillus species

2016
openaire   +1 more source